Melvin Chua: Progress in Focal Therapy for Prostate Cancer Can Be Made by Good Science
Melvin Chua, Head of the Department of Head, Neck and Thoracic Cancers at the National Cancer Centre Singapore, shared a post on X about a paper he co-authored, published in the Journal of the National Cancer Center:
“Very proud to see this finally in press by my mentee and fellow Clinician-Scientist Kae Jack Tay. In a domain where Focal Therapy in Prostate Cancer remains controversial and divisive, progress can be made by good Science, thanks to the Decipher by Veracyte team.”
Title: Transcriptomic predictors of prostate cancer recurrence following focal cryotherapy: a pooled analysis of phase II trial and prospective cohort data
Authors: Kae Jack Tay, Boon Hao Hong, Enya Hui Wen Ong, Kah Min Tan, Gianella Cabuhat Pacho, Samantha Jingxuan Wong, Yu Guang Tan, Yan Mee Law, Nye Thane Ngo, Puay Hoon Tan, John S.P. Yuen, Henry S.S. Ho, Kenneth Chen, Jiping Peng, Clare Wei Tian Foo, Xin Xiu Sam, Jeffrey K.L. Tuan, Ravindran Kanesvaran, Rajan T. Gupta, Steven Rozen, Thomas J. Polascik, Yang Liu, James Proudfoot, Elai Davicioni, Li Yan Khor, Melvin Lee Kiang Chua
You can read the Full Article in the Journal of the National Cancer Center.
More posts featuring Melvin Chua.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023